Gossamer Bio (NASDAQ:GOSS) Cut to Hold at The Goldman Sachs Group

The Goldman Sachs Group downgraded shares of Gossamer Bio (NASDAQ:GOSS) from a strong-buy rating to a hold rating in a research report sent to investors on Tuesday,Zacks.com reports.

Several other research firms also recently weighed in on GOSS. Barclays downgraded Gossamer Bio from an “overweight” rating to an “underweight” rating in a research report on Tuesday. Leerink Partners lowered shares of Gossamer Bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Royal Bank Of Canada raised shares of Gossamer Bio to an “outperform” rating in a research report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Gossamer Bio in a report on Thursday, January 22nd. Finally, Wedbush reaffirmed a “neutral” rating and set a $1.00 price target (down from $6.00) on shares of Gossamer Bio in a research report on Tuesday. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $6.67.

Gossamer Bio Stock Performance

Shares of GOSS opened at $0.40 on Tuesday. Gossamer Bio has a fifty-two week low of $0.33 and a fifty-two week high of $3.87. The company has a market capitalization of $93.05 million, a PE ratio of -0.58 and a beta of 1.93. The stock has a fifty day moving average of $2.47 and a two-hundred day moving average of $2.63.

Institutional Investors Weigh In On Gossamer Bio

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in shares of Gossamer Bio by 5.2% in the third quarter. Vanguard Group Inc. now owns 12,009,773 shares of the company’s stock worth $31,586,000 after acquiring an additional 598,981 shares in the last quarter. State Street Corp increased its holdings in Gossamer Bio by 139.7% in the 4th quarter. State Street Corp now owns 9,310,969 shares of the company’s stock valued at $28,864,000 after purchasing an additional 5,427,302 shares in the last quarter. Acadian Asset Management LLC raised its position in Gossamer Bio by 12.4% in the second quarter. Acadian Asset Management LLC now owns 7,146,022 shares of the company’s stock valued at $8,786,000 after purchasing an additional 787,909 shares during the period. Geode Capital Management LLC lifted its stake in shares of Gossamer Bio by 3.9% during the fourth quarter. Geode Capital Management LLC now owns 4,872,714 shares of the company’s stock worth $15,109,000 after purchasing an additional 183,183 shares in the last quarter. Finally, Corient Private Wealth LLC lifted its stake in shares of Gossamer Bio by 19,123.7% during the fourth quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock worth $11,922,000 after purchasing an additional 3,825,879 shares in the last quarter. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.